In key news on Australian stocks, Goodman Group (AU:GMG) reported a strong Q3 update for FY24, signalling optimism for its business for the ful ...

The sBLA submission in the US is based on positive Phase III trial of Ultomiris in gMG, which were announced by AstraZeneca's Rare Disease group, Alexion, in July 2021.

The company noted that CHMP has recommended European Commission approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized gMG who are anti ...